TABLE 1.
Bacterial activity of pyocin S8 against MDR Pseudomonas aeruginosa strains isolated from clinical and environmental samples
| P. aeruginosa strain | Source | Resistance profile fora: |
β-Lactamaseb | Bacterial activity of pyocinsc: |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPM | MEM | CAZ | FEP | AK | GEN | LVX | CIP | S8 | S2, S4, S5d | |||
| 48-1997A | Human | R | R | R | R | R | R | R | R | SPM-1 | + | – |
| 247-B | Human | R | R | R | I | S | R | R | R | VIM-1 | + | – |
| GIM | Human | R | R | R | R | I | R | R | R | GIM-1 | + | – |
| BH6 | Human | R | R | R | R | R | I | R | R | KPC-2 | + | – |
| PHB64 | Human | R | R | R | R | R | R | R | R | GES-5 | + | – |
| IMP | Human | R | R | R | R | R | R | R | I | IMP-1 | + | – |
| 298 | Human | I | R | R | R | S | I | S | S | OXA-18 | + | – |
| 395 | Human | R | R | R | R | R | R | R | R | IMP-18 | – | – |
| 179 | Human | R | R | R | R | R | R | R | R | VIM-1 | + | – |
| 1088 | Human | R | R | R | R | S | I | R | R | SPM-1 | + | – |
| 392 | Human | R | R | I | R | S | R | R | R | OXA-10 | – | – |
| 225 | Human | R | R | R | R | R | R | R | R | GES-1 | + | – |
| 44 | Human | R | R | R | R | R | R | R | R | SPM-1 | + | – |
| 19 | Environmental | R | R | R | R | R | R | R | R | SPM-1 | + | – |
| 141 | Environmental | R | R | R | R | R | R | R | R | SPM-1 | – | – |
| 151 | Environmental | R | R | R | R | R | R | R | R | SPM-1 | + | – |
| ET02 | Human | S | S | S | R | S | I | I | S | OXA-50 | – | + |
| PAO1 | Control | S | S | S | S | S | S | S | S | OXA-50 | + | – |
a
IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; AK, amikacin; GEN, gentamicin; LVX, levofloxacin; CIP, ciprofloxacin (21); R, resistant isolates; I, intermediate isolates; S, susceptible isolates.
b
Genes encoding β-lactamases were confirmed by PCR and sequencing.
c
Bacterial activity of pyocins was evaluated by the presence (+) or absence (–) of inhibition zones measuring ≥10 mm, using a pyocin assay (5).
d
Pyocins produced by P. aeruginosa strain PAO1 (9).